Independent Pharmacy Roll-Up — Acquisition Thesis
Buy-and-build consolidation of independent community pharmacies, sourced via a proprietary AI screening engine I built.
Pursue a buy-and-build roll-up of independent community pharmacies, using the AI screening engine to acquire owner-operated stores off-market at low-single-digit EBITDA multiples, integrate them onto a shared purchasing and clinical platform, and exit a scaled regional operator at a higher multiple. A focused 25–35-store platform is achievable in 4–5 years; the edge is proprietary deal flow, not capital. The return hinges on exit-multiple expansion, which current retail-pharmacy comps work against, so the honest base case is ~2.0× MOIC at a modest ~5× exit, with downside near capital-preserving if multiples stay compressed.
~19,000 independent community pharmacies (NCPA 2025) generate ~$103B in annual revenue — a fragmented, owner-operated market consolidating at more than one closure a day. Owners are operators, not financial sellers, so processes are uncompetitive and pricing is negotiable. Fragmentation plus a retirement wave is the classic roll-up setup.
My platform scores a ~65k-record universe of non-chain pharmacies on a 6-factor model. I rejected normalization methods that inflated the target list to 25k–50k stores and kept a deliberately conservative score — isolating just 820 high-conviction targets, with the top 100 holding 83–85% stable under ±10% stress. The discipline is the moat: a short, vetted, off-market pipeline.
The 820 targets share a clear signature versus the field: 86% show stale licensing records (a retirement / disengagement proxy) and serve higher-income ZIPs ($98k vs $66k median), a profile that reads more suburban than rural. [[TODO: confirm the local-competition metric; the prior "2.6 vs 14.9 per 10k" figure looks off, since ~2.6/10k is close to the U.S. average and should not be cited as low-competition evidence.]]
Two reference points, not cross-checks; they can differ 3–5×. A file buy at ~$3–5 per annual script sets a downside floor (chains pay $5–12+ in competitive deals). A whole-business, going-concern buy at ~2.5–4.0× EBITDA plus inventory is the operating price we actually underwrite. Independents run ~22% gross margin (NCPA), so entry margins are thin with room to expand. Base entry: ~3.5× EBITDA.
Illustrative Exit-Multiple Sensitivity
| Exit multiple | Scenario | MOIC |
|---|---|---|
| ~3.5× (flat, no expansion) | Downside | ~1.0–1.3× |
| ~5.0× (modest) | Base | ~2.0× |
| ~7.5× (current comps) | Upside | ~3.0× |
Holds a ~30-store, ~6%-margin build at ~3.5× entry constant and varies only the exit. The return is driven by multiple expansion, so exit is the swing factor and the primary risk: retail-pharmacy comps have compressed (Rite Aid's bankruptcy, Walgreens taken private, CVS under margin pressure). A true downside that also pushes margin below entry (~3–4%) and exit toward ~4× lands near ~1.0× MOIC or below. Pace check: 820 scored targets at a ~6% win rate is ~49 reachable, so a 30-store build is disciplined, not heroic.
Value-Creation Plan
- Purchasing scale: modest GPO / wholesaler gains on a ~78% COGS base, haircut because buying groups already capture most independent GPO pricing (~+50–75 bps, illustrative)
- Central fill & shared back office: ~$50–80k saved per store, the most reliable lever
- DIR-fee timing & appeals: treated as timing and recovery only, not a structural margin lever; PBM / DIR economics are Risk #1 below, not a lever
- Net target: illustrative lift from ~4% toward ~5% of revenue, contingent on the above [[TODO: confirm net margin target]]
Structure & Pacing
- Leverage: [[TODO: confirm assumed acquisition leverage / debt structure]]; if SBA 7(a), each loan caps at $5M
- Deployment: gradual, roughly 6–8 stores per year over 4–5 years, not a single close
- Platform G&A: central-fill, compliance, and integration overhead [[TODO: confirm platform overhead]]
Key Risks & Mitigants
- PBM & DIR pressure (CMS 2024 reforms; state PBM-delinking laws) → diversify into cash-pay clinical services
- Generic deflation → purchasing scale plus a richer service mix
- Amazon / mail-order → focus on high-touch local and rural markets
- 340B is upside only, not core EBITDA — given the 2024 appellate ruling on manufacturer restrictions and HRSA's 2026 rebate-model pilot
- Integration & pharmacist retention → earnouts, retention packages, phased onboarding (base case assumes modest post-close attrition)
Assumptions & Limitations
Illustrative case study — not a live deal or a forecast. Market context from the NCPA 2024–2025 Digest, CMS, and Drug Channels; valuation and return assumptions reflect 2024–2026 comparables and are clearly bounded. Target counts and screening signals are outputs of my proprietary, un-audited model. Returns are scenario estimates, highly sensitive to store count, margin capture, and exit multiple.